Skip to main content

Month: April 2023

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma Initial clinical data for LAVA-1207, a Phase 1/2a dose escalation clinical trial in patients with therapy refractory metastatic castration-resistant prostate cancer, suggest a favorable safety profile and initial signs of clinical activity, with PSA levels stabilizing or decreasing in highly pre-treated patients Announced license agreement with Seagen for the development of LAVA-1223 in exchange for $50 million upfront; up to approximately $650 million in potential milestones; and royalties Strong balance sheet with cash and investments of $132.9 million as of December 31, 2022, expected...

Continue reading

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to shareholders and other stakeholders. All dollar amounts in this news release are in US dollars unless specified otherwise. Preliminary revenue estimates for fiscal year 2023 and fiscal Q4 2023 Medexus expects to deliver total revenue between $107 million and $108 million for fiscal year 2023, representing record annual revenue for Medexus and a year-over-year increase...

Continue reading

Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial

Pivotal Phase 3 trial of MVA-BN® RSV has accrued enough cases required for efficacy analysis Topline results expected around mid-2023COPENHAGEN, Denmark, April 11, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Phase 3 clinical trial of MVA-BN® RSV, the Company’s investigational vaccine for the prevention of respiratory syncytial virus (RSV) in adults ≥60 years of age, has now accrued the number of cases required to complete the primary efficacy analysis, which is expected around mid-2023. Adjudicated data have confirmed enough cases with both 2+ symptoms and 3+ symptoms as required in the trial. The global, randomized, placebo-controlled, double-blind Phase 3 VANIR clinical trial has enrolled more than 20,000 participants across more than 100 centers in the U.S. and Germany. The primary objective of the study will...

Continue reading

Changes to KommuneKredit’s Board of Directors as of 1 April 2023

The election period for KommuneKredit’s Board of Directors follows the election period for municipal and regional councils staggered by 5 months. The current election period runs from 1 June 2022 to 31 May 2026. 6 board members are elected by the municipalities, 2 by the regions and 2 independent members – possessing qualifications within accounting, auditing, financial or risk management – are elected by the Board of Directors. As of 1 April 2023, the composition of the Board of Directors will change as follows: Martin Geertsen (Capital Region of Denmark) has resigned from the Board of Directors in accordance with KommuneKredits articles of association section 13 subsection 1 due to his resignation from the regional council. As of 1 April 2023, the regions have elected regional council member Carsten Scheibye, (Capital Region of Denmark)...

Continue reading

Emerging Markets Report: The Mastermind Behind the Brand

An Emerging Markets News Commentary ORLANDO, Fla., April 11, 2023 (GLOBE NEWSWIRE) — Previously, we introduced Kisses From Italy Inc. (OTCQB:KITL), a publicly listed U.S.-based company, restaurant chain operator, franchisor, and product distributor with locations in the United States, Canada and Europe, and its partnership with celebrity chef, Food Network Star, restaurateur and cookbook author Scott Conant. Now, it is time for the company’s current advisor, Fransmart, to have the spotlight. Fransmart is a global leader in franchise development, selling over 5,000 franchises worldwide and turning emerging restaurant concepts into national and global brands for 20 years. The company serves as Kisses From Italy’s current advisor and exclusive global developer and representative, aiding brand development and growth. Fransmart’s website...

Continue reading

Aravive Appoints Carolina Petrini as Chief Commercial Officer

HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company’s new Chief Commercial Officer effective April 10, 2023. Ms. Petrini brings over two decades of experience in developing pre-commercial, launch readiness and commercial strategies, building and leading high-performing commercial teams. “We are delighted to welcome Carolina as our new Chief Commercial Officer,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “With her extensive experience in oncology and exceptional track record of success in developing global commercial and launch strategies, we are confident that she will be a valuable asset to Aravive as...

Continue reading

Teekay Group Publishes 2022 Sustainability Report and Announces Availability of Annual Reports on Form 20-F for the Year Ended December 31, 2022

HAMILTON, Bermuda, April 11, 2023 (GLOBE NEWSWIRE) — Teekay Corporation (Teekay) (NYSE:TK) and Teekay Tankers Ltd. (Teekay Tankers) (NYSE:TNK) (collectively, the Teekay Group) today announced the publication of their 2022 Sustainability Report, which can be accessed on the Teekay Group’s website by clicking here. In addition, the Teekay Group has released their Annual Reports on Form 20-F for the fiscal year ended December 31, 2022 (Annual Reports), each of which has been filed with the U.S. Securities and Exchange Commission and can be accessed at www.teekay.com, in the “Investors” section under “Financials and Presentations” for each respective entity. Shareholders may also request hard copies of the Annual Reports, which include the Teekay Group’s complete 2022 audited financial statements, free of charge, by contacting Investor...

Continue reading

GFG Drills High-Grade Gold on First Drill Test at Aljo, Extends Montclerg 1 km East & Resumes Drilling in Timmins

Figure 1: Regional Map of GFG Gold Projects in the Timmins Gold District GFG Resources Inc. Gold Projects in the Timmins Gold DistrictFigure 2: Goldarm Property Plan View Map GFG Resources Inc. Goldarm Property MapFigure 3: Montclerg Gold Project Plan View Map GFG Resources Inc. Montclerg Gold Project MapFigure 4: Aljo Target Plan View Map(1) GFG Resources Inc. Aljo Gold Target MapKEY HIGHLIGHTS:First pass drilling at the Aljo Mine Target (“Aljo”) successfully returned high-grade gold intervals at shallow depths across multiple vein systems along with broader intervals of low-grade mineralization.ALJ-22-002: 3.03 grams per tonne gold (“g/t Au”) over 12.9 metres (“m”) including 59.80 g/t Au over 0.60 m and 6.58 g/t Au over 4.3 m including 27.4 g/t Au over 1.0 mHole MTC-22-044 successfully confirmed gold mineralization...

Continue reading

Scorpio Tankers Inc. Announces the Exercise of Purchase Options on Six Ships and Repurchases of Its Common Shares

MONACO, April 11, 2023 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) announced today that it has exercised the purchase options on six ships and that it has repurchased its common shares in the open market. The Exercise of Purchase Options The Company has given notice to exercise its purchase options on one 2019 built LR2 product tanker (STI Lobelia) and five 2019 built MR product tankers (STI Magic, STI Mystery, STI Marvel, STI Mythic, and STI Magister). The leases bear interest at LIBOR plus a margin of 3.50% per annum. The purchases, which are expected to occur in June 2023, will result in a debt reduction of $147.3 million for the Company. Repurchase of Common Shares Recently, the Company purchased 396,706 of its common shares in the open market at an average price of $54.41 per share...

Continue reading

Form 8.3 – [Devro plc – 06 04 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.